... patients. A pooled analysis of 9 RCTs, comparing duloxetine with placebo for 8–9 weeks, found duloxetine produced significantly greater baseline-to-endpoint mean change ...

... nm] OR “venlafaxine”[nm] OR “escitalopram”[tw] OR “duloxetine”[nm] OR “trazodone”[mh] OR antidepressive agents, second- ... mirtazapine[nm] OR venlafaxine[nm] OR escitalopram OR duloxetine[nm] OR trazodone[mh] AND “depressive disorder”[mh] ...

... 303. Harada, E, Tokuoka, H, et al. Is duloxetine’s effect on painful physical symptoms in depression ... Eiji, Schacht, Alexander, et al. Efficacy comparison of duloxetine and SSRIs at doses approved in Japan. Neuropsychiatric ...

... or pregabalin).ab,kw,sh,ti. (desvenlafaxine or duloxetine or levomilnacipran or milnacipran or venlafaxine).ab,kw, ... or pregabalin).ab,kw,sh,ti. (desvenlafaxine or duloxetine or levomilnacipran or milnacipran or venlafaxine).ab,kw, ...

... a small improvement in function versus pregabalin (plus duloxetine as needed) in two trials [1 new]; differing ... acceptance and commitment therapy (ACT) with pregabalin (plus duloxetine as needed) several mild adverse events were noted ...

... fluoxetine and sertraline), serotonin – norepinephrine reuptake inhibitors (SNRIs) (duloxetine and venlafaxine), bupropion extended release (XR), mirtazapine, trazodone ...

... withdrawals due to adverse events with escitalopram or duloxetine (low SOE) but was associated with greater incidence ... analysis on a RCT, risk of falls on duloxetine may be associated with the presence of any ...

... within previously reviewed classes (e.g., the antidepressant duloxetine and the antiseizure medication pregabalin). Because of the ... inhibitor class. Evidence from several trials indicates that duloxetine is more effective than placebo for pain and ...

... day for 8 weeks, 141 and the SNRI duloxetine, 120 mg/day for 12 weeks. 96 All ... groups. 89 Other second-generation antidepressant trials included duloxetine and bupropion. Duloxetine (120 mg/day for 12 ...

... antidepressants in clinical practice including SSRIs, TCAs, MAOIs, duloxetine, venlafaxine, bupropion, reboxetine, mirtazapine, trazodone, mianserin and psychostimulants ( ...